382 PROLONGED INTRAHEPATIC HEPATITIS DELTA ANTIGEN PERSISTENCE AFTER LIVER TRANSPLANTATION (LTX) DESPITE RAPID EARLY SERUM HDVRNA DECLINE AFTER LTX

months. Out of 4 patients with HBV reactivation, 2 patients were treated with entecavir because they showed persistent increase in HBVDNA load. In the remaining 2 patients, HBVDNA level indicated transient elevations, and then decreased below the lower limit for quantification during close follow-up. None of 4 patients with HBV reactivation presented de novo hepatitis. Conclusions: In the patients with lymphoma or multiple myeloma, incidence of HBV reactivation was 6.8%, when anti-HBc were present prior to chemotherapy. Because patients with anti-HBc might be at high risk of HBV reactivation, they should be monitored closely for HBV-DNA levels during and after rituximab and steroid-containing treatment.